Mahesh Seetharam, MD
Hematology & Oncology · Phoenix, AZNPI 1487781175
Payments from drug & device makers
Across 490 payments — averaging $3576.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Deciphera Pharmaceuticals Inc.$856K
- Blueprint Medicines Corporation$193K
- AbbVie$188K
- Immunocore Limited$135K
- Macrogenics, Inc.$108K
- Merck$44K
- plus $228K from 19 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Deciphera Pharmaceuticals Inc. | 208 | $856,120 |
| Blueprint Medicines Corporation | 30 | $193,163 |
| AbbVie | 15 | $187,791 |
| Immunocore Limited | 60 | $135,407 |
| Macrogenics, Inc. | 11 | $107,988 |
| Merck | 94 | $43,523 |
| Regeneron | 28 | $36,641 |
| E.r. Squibb & Sons, L.L.C. | 2 | $31,750 |
| Hoffmann-la Roche Limited | 5 | $31,110 |
| Boehringer Ingelheim | 2 | $28,760 |
| AstraZeneca | 2 | $27,777 |
| Modernatx, Inc. | 1 | $27,500 |
| Pfizer | 1 | $21,400 |
| Daiichi Sankyo Inc. | 12 | $8,167 |
| Bavarian Nordic A/s | 2 | $6,200 |
| Springworks Therapeutics, Inc. | 7 | $5,112 |
| Bayer | 2 | $2,100 |
| Aadi Bioscience, Inc. | 1 | $1,000 |
| Boehringer Ingelheim Pharma GmbH & Co.kg | 1 | $568 |
| Tempus AI, Inc | 1 | $127 |
| Genentech USA, Inc. | 1 | $127 |
| Novartis | 1 | $34 |
| Beone Medicines USA, Inc. | 1 | $32 |
| Lilly USA, LLC | 1 | $14 |
| Gilead | 1 | $12 |
How this compares
$1,752,423 in reported general payments places this provider in the 85th percentile of 261 hematology & oncology providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other hematology & oncology in Phoenix
- Javier MunozPhoenix$8.4M
- Donald NorthfeltPhoenix$1.7M
- Panayiotis SavvidesPhoenix$1M
- Tanios Bekaii-SaabScottsdale$31.4M
- Yousef ZakhariaScottsdale$13M
- Jiaxin NiuGilbert$10.7M
- Sudhir MandaTucson$10M
- Parminder SinghScottsdale$9.7M
- Michael GordonScottsdale$9.2M
- Mikhail ShtivelbandChandler$9.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.